Form4insider filings, from the source

SEC Form 4 · accession 0000899243-19-004404

TCR2 THERAPEUTICS INC. · TCRR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owners
Morana Jovan-Embiricos
Director · 10% Owner
F2 MG Ltd
10% Owner
F2 BBG LLC
10% Owner
Period of report
Feb 19, 2019
Accepted (ET)
Feb 21, 2019 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001750019

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Feb 19, 2019C1,614,515—A1,614,515IBy Fund
Common StockF3,F4Feb 19, 2019C193,742—A193,742IBy Fund
Common StockF3,F5Feb 19, 2019C410,168—A410,168IBy Fund
Common StockF3,F6Feb 19, 2019C282,540—A282,540IBy Fund
Common StockF3,F7Feb 19, 2019C403,629—A403,629IBy Fund
Common StockF8Feb 19, 2019P200,000$15.00A200,000IBy Fund
Common StockF9Feb 19, 2019P166,667$15.00A166,667IBy Fund
Common StockF6Feb 19, 2019P166,667$15.00A449,207IBy Fund
Common StockF7Feb 19, 2019P133,333$15.00A536,962IBy Fund

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A Preferred StockF1,F2—Feb 19, 2019C10,000,001D——Common Stock1,614,5150I
Series B Preferred StockF3,F4—Feb 19, 2019C1,200,000D——Common Stock193,7420I
Series B Preferred StockF3,F5—Feb 19, 2019C2,540,500D——Common Stock410,1680I
Series B Preferred StockF3,F6—Feb 19, 2019C1,750,000D——Common Stock282,5400I
Series B Preferred StockF3,F7—Feb 19, 2019C2,500,000D——Common Stock403,6290I

Explanation of responses